Operational improvements are clear (revenue growth, margin stability, customer growth) but the massive uncertain tax position and ongoing net losses temper the positive read-through. Watch for updates on the IRS's position on Section 280E rescheduling and the June 29, 2026 DEA hearings on adult-use cannabis. Positive cash flow suggests no near-term liquidity crisis, but the tax overhang could constrain capital allocation.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Jun 12 $0.2700entry
- T+1 · 5mo ago −7.78%α −9.54% · $0.2490
- T+5 · 5mo ago −8.70%α −9.32% · $0.2465
- T+20 · 4mo ago −11.56%α −12.82% · $0.2388
- T+60 · due 2mo ago Pending
Price Chart
How similar events traded
Executive Summary
C21 Investments reported FY2026 results with revenue of $32.6M (+8.3% YoY), operating income of $2.3M (+78% YoY), and Adjusted EBITDA of $5.5M (+13% YoY). The company generated positive operating cash flow of $1.36M and improved to a working capital surplus of $1.9M from a $0.5M deficit last year. However, a $4.6M income tax expense (driven by the company's position that IRC Section 280E does not apply) kept net loss at $3.2M, and the uncertain tax liability grew to $13.4M. The filing also notes the recent rescheduling of medical marijuana to Schedule III, which could reduce tax burden over time.
Key Facts
- Revenue increased 8.3% to $32.6M (FY2026 vs FY2025: $30.1M)
- Gross margin stable at 41.7%
- Income from operations rose 78% to $2.3M
- Net loss narrowed to $3.2M from $4.0M
- Adjusted EBITDA grew 13% to $5.5M
- Positive operating cash flow of $1.36M (flat YoY)
- Working capital surplus of $1.9M vs deficiency of $0.5M last year
- Record 725,000 customer transactions (up 16% YoY)
- Uncertain tax position ballooned to $13.4M due to Section 280E challenge
- Convertible debentures reduced to $732,638 (all current) from $1.69M last year
- DEA rescheduled medical marijuana to Schedule III on April 28, 2026
- Litigation settlement (EFF) resulted in $443K loss; $1.1M paid during the year
Financial Impact
Revenue up $2.5M, operating income up $1.0M, net loss reduced by $0.7M. Tax overhang of $13.4M remains unresolved.
Risk Factors
- IRS challenge to the Section 280E tax position could require large cash outflows
- Adult-use cannabis remains federally illegal; enforcement risk persists
- Price compression in Nevada market and state sales down 10% YoY
- High debt service on convertible debentures ($1.3M repaid in FY2026)
- Accumulated deficit of $80M and negative shareholders' equity of $25.4M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001062993-26-003165 |
| Exhibit: exhibit99-2.htm | 0001062993-26-003165 |
| Exhibit: exhibit99-5.htm | 0001062993-26-003165 |
Track record
4 reports on CXXIF
The track record builds as more bullish or bearish reports settle.
Filters
- Aug 21, 202612w ago 6-K Bearish 5/10 Entry $0.2590 No price data
- Jun 15, 202622w ago 6-K Bullish 7/10 Entry $0.2490 to $0.2390 ▼ −4.02% −3.88% vs SPY
- Jun 12, 202622w ago 20-F Mixed 5/10 Entry $0.2700 to $0.2388 ▼ −11.56% −12.82% vs SPY
- Jun 12, 202622w ago 6-K Mixed 5/10 Viewing Entry $0.2700 to $0.2388 ▼ −11.56% −12.82% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers